Mesa Laboratories, Inc.

NasdaqGS MLAB

Mesa Laboratories, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 58.57%

Mesa Laboratories, Inc. Gross Profit Margin is 58.57% for the Trailing 12 Months (TTM) ending September 30, 2024, a -3.17% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.
  • Mesa Laboratories, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 60.49%, a 2.50% change year over year.
  • Mesa Laboratories, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 59.01%, a -7.07% change year over year.
  • Mesa Laboratories, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was 63.50%, a 8.71% change year over year.
  • Mesa Laboratories, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was 58.41%, a -2.48% change year over year.
Key data
Date Gross Profit Margin Operating Income Margin EBT Margin Net Income Margin
Market news
Loading...
NasdaqGS: MLAB

Mesa Laboratories, Inc.

CEO Mr. Gary M. Owens
IPO Date Feb. 29, 1984
Location United States
Headquarters 12100 West Sixth Avenue
Employees 736
Sector Health Care
Industries
Description

Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Similar companies

BMI

Badger Meter, Inc.

USD 209.78

1.49%

VPG

Vishay Precision Group, Inc.

USD 22.64

0.85%

VNT

Vontier Corporation

USD 36.35

1.65%

FTV

Fortive Corporation

USD 77.35

1.66%

ITRI

Itron, Inc.

USD 104.87

1.46%

ST

Sensata Technologies Holding plc

USD 27.74

1.02%

ESE

ESCO Technologies Inc.

USD 132.60

1.94%

NOVT

Novanta Inc.

USD 148.22

1.40%

COHR

Coherent, Inc.

USD 93.00

1.03%

StockViz Staff

January 15, 2025

Any question? Send us an email